Paris, France

Norio Uematsu

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignees: Centre National De La Recherche Scientifique, Institut Curie, National Institute for Agricultural Research. Active years: 2007.


% Patents Active = 100.0


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Norio Uematsu: Innovator in Meiotic Recombination

Introduction

Norio Uematsu is a prominent inventor based in Paris, France. He has made significant contributions to the field of genetics, particularly in the area of meiotic recombination. His innovative work has implications for various biological and medical applications.

Latest Patents

Uematsu holds a patent titled "Methods for inducing targeted stimulation of meiotic recombination and kits for performing said methods." This invention pertains to methods, kits, molecules, and cells designed to increase the rate of recombination and target recombination in dividing cells. Specifically, it focuses on methods and kits to induce targeted meiotic recombination.

Career Highlights

Throughout his career, Uematsu has worked with esteemed organizations such as the Centre National de la Recherche Scientifique and the National Institute of Health and Medical Research. His experience in these institutions has allowed him to advance his research and contribute to the scientific community.

Collaborations

Uematsu has collaborated with notable colleagues, including Kathleen Smith and Michèle Vedel. These partnerships have enriched his research and fostered innovation in his field.

Conclusion

Norio Uematsu is a distinguished inventor whose work in meiotic recombination has the potential to impact various scientific and medical fields. His contributions continue to inspire advancements in genetic research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…